Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidenceIf approved, Rezurock would offer a new treatment option in the EU for adult patients and in children aged 12 years and older in late line chronic GVHD Paris, January 30, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending ...

Core Viewpoint - Lexicon Pharmaceuticals, Inc. has announced a public offering of 32 million shares at a price of $1.30 per share, aiming to raise approximately $41.6 million before expenses [1] Group 1: Public Offering Details - The public offering consists of 32,000,000 shares priced at $1.30 each, with expected gross proceeds of $41.6 million [1] - The offering is set to close on or about February 2, 2026, pending customary closing conditions [1] - Underwriters have a 30-day option to purchase an additional 4,800,000 shares at the public offering price [1] Group 2: Concurrent Private Placement - Lexicon will also conduct a concurrent private placement, selling 22,400,000 shares of common stock and 184,366 shares of Series B Convertible Preferred Stock for expected gross proceeds of approximately $41.1 million [2] - The Series B Convertible Preferred Stock will convert into 9,218,290 shares of common stock, with an additional option for the purchaser to buy more shares [2] - The private placement is also scheduled to close on or about February 2, 2026, and is not contingent on the public offering [3] Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be used to fund ongoing research and development of drug candidates, as well as for working capital and general corporate purposes [4] Group 4: Regulatory Information - A shelf registration statement for the public offering was filed with the SEC and declared effective [5] - The securities offered in the private placement will not be registered under the Securities Act [3]

Core Insights - Zai Lab Limited (NASDAQ:ZLAB) is recognized as one of the top high-growth Chinese stocks, with UBS initiating coverage with a Buy rating and a price target of $35, highlighting its shift from a China-centric strategy to a global innovation focus [1] - UBS believes Zai Lab is undervalued due to recent disappointments in the Chinese market and that the global pipeline offers significant long-term value that the market has not fully recognized [2] Company Overview - Zai Lab Limited is a commercial-stage biopharmaceutical company operating in China and the United States, dedicated to developing therapies for significant unmet medical needs in oncology, immunology, neuroscience, and infectious diseases [3] Market Trends - The global pipeline indicates a movement towards high-value, innovative treatments that could redefine Zai Lab's development trajectory over the next decade [2]

Core Insights - Ascendis Pharma A/S (NASDAQ:ASND) is recognized as a high-growth European stock, with RBC Capital raising its price target to $250 from $245 while maintaining an Outperform rating [1] Group 1: Market Potential - The European market for Ascendis Pharma A/S is projected to be significantly larger, with an estimated 150,000-200,000 patients compared to 70,000-90,000 in the U.S., although the complex payer system may require patience [2] - The company anticipates a revenue split of 60% from the U.S. and 40% from non-U.S. markets [2] Group 2: Financial Projections - Ascendis Pharma A/S aims for €500 million in operating cash flow for the current year and over €5 billion in top-line revenue by 2030, exceeding the consensus estimate of approximately €3.5 billion [3] - Yorvipath is expected to generate between €5 billion and €8 billion at its peak [3] Group 3: Company Overview - Ascendis Pharma A/S is a biopharmaceutical company focused on developing and distributing innovative treatments for unmet medical needs, particularly in oncology and endocrinology [3]

Core Viewpoint - POXEL SA has successfully exited judicial reorganisation proceedings, with the recovery plan ratified by the Commercial Court of Lyon, allowing the company to focus on its commercial development and settle its liabilities [1][2][3]. Recovery Plan Key Elements - The recovery plan includes business development, cost structure optimisation, and settlement of outstanding liabilities [4]. - The company aims to establish new partnerships for the commercialisation of Imeglimin in Asia, particularly in China, and promote PXL770 for ADPKD while leveraging the value of PXL065 in HCM [6]. Financial Structure Strengthening - Measures include a €5 million equity line over five years from IRIS, new bond borrowings of €3.75 million from IPF, and a capital increase with maintenance of shareholders' preferred subscription rights [5][6]. - The company plans to convert part of the IPF debt into shares and settle other creditors according to an agreed repayment schedule [6]. Company Overview - POXEL is a clinical stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology, including MASH and rare disorders [8]. - The company’s product pipeline includes PXL065, PXL770, and Imeglimin, with Imeglimin already marketed in Japan through a partnership with Sumitomo Pharma [8].

Core Insights - Idorsia Ltd announces the presentation of long-term results from the lucerastat treatment at the 22nd Annual WORLDSymposium™, highlighting its potential as a first-in-class oral substrate reduction therapy for Fabry disease [1][7] Study Overview - The MODIFY study was a multicenter, double-blind, randomized, placebo-controlled trial involving 118 patients to assess the efficacy and safety of lucerastat as an oral monotherapy for Fabry disease [3] - The study did not meet its primary endpoint of reducing neuropathic pain but showed significant reductions in plasma and urinary Gb3 levels compared to placebo, sustained over time in the open-label extension [4][14] Long-term Efficacy - An interim analysis of the open-label extension revealed a notable reduction in the rate of eGFR decline among patients treated with lucerastat, suggesting a potential disease-modifying effect [5] - Patients with impaired renal function at baseline experienced a marked attenuation of kidney function loss, indicating lucerastat's promise in long-term organ protection [5][14] Kidney Biopsy Sub-study - A kidney biopsy sub-study evaluated Gb3 accumulation in key kidney cell types in male patients with classic Fabry disease who received lucerastat for at least two years, providing insights into its impact on renal disease biology [2] Patient Population and Disease Background - Fabry disease is a rare, X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to the accumulation of Gb3 and progressive damage across multiple organ systems [6][8] - Recent studies suggest a higher prevalence of Fabry disease than previously estimated, with over 21,000 diagnosed patients expected across the US, EU5, and Japan by 2034 [9] Current Treatment Landscape - Current treatment options for Fabry disease include enzyme replacement therapies and oral chaperone therapy, which have limitations, highlighting the unmet need for a well-tolerated, oral, disease-modifying therapy [10][11]

Group 1 - Nuvation Bio Inc. (NYSE:NUVB) is recognized as a high short interest stock with significant upside potential, particularly due to the performance of its Ibtrozi franchise [1] - Truist raised its price target for Nuvation Bio to $13 from $11, maintaining a Buy rating, citing strong market uptake for Ibtrozi as a preferred ROS1 agent [1] - RBC Capital analyst increased the price target for Nuvation Bio to $12 from $9 with an Outperform rating after discussions with management, leading to updates in financial models for the biotech sector [2] Group 2 - H.C. Wainwright adjusted its price target for Nuvation Bio to $17 from $18 while keeping a Buy rating, noting that preliminary Q4 Ibtrozi net product revenue was approximately $15.7 million, aligning with expectations [3]

Core Insights - Mineralys Therapeutics Inc. (NASDAQ:MLYS) is recognized as a high short interest stock with significant upside potential, particularly following the announcement of its NDA filing for lorundrostat in late 2025 [1] - The company has achieved several clinical milestones, including the completion of three positive trials that demonstrated the drug's efficacy in blood pressure control and safety across diverse patient populations [1] - Analysts from Bank of America and Stifel have raised their price targets for Mineralys, indicating positive market sentiment and potential for growth [2][3] Group 1: Company Developments - Mineralys Therapeutics announced the late 2025 filing of its NDA for lorundrostat, which is a significant step in its drug development process [1] - The company has completed three positive clinical trials: Explore-CKD, Launch-HTN, and Advance-HTN, showcasing the drug's 24-hour blood pressure control and safety [1] - Mineralys is on track to report topline results from its Phase 2 Explore-OSA trial in Q1 2026 and is gathering long-term data through its Transform-HTN open-label extension trial [1] Group 2: Analyst Ratings and Price Targets - Bank of America raised its price target on Mineralys Therapeutics to $46 from $43, maintaining a Buy rating, citing the company's Q3 2025 results and confirmed cash runway into 2027 [2] - Stifel also increased its price target for Mineralys to $52 from $45 while keeping a Buy rating, reflecting a positive outlook for the firm's Biopharma coverage [3]

Core Viewpoint - Apellis Pharmaceuticals Inc. is recognized as a high short interest stock with significant upside potential, particularly due to the promising commercial prospects of its drug Empaveli in treating rare kidney diseases [1]. Group 1: Analyst Ratings and Price Targets - Bank of America upgraded Apellis to Buy from Neutral with an unchanged price target of $28, emphasizing the market's undervaluation of Empaveli's commercial prospects [1]. - Wells Fargo reduced its price target for Apellis to $26 from $29 while maintaining an Overweight rating, citing a slower-than-expected commercial ramp for Empaveli in specific indications [2]. Group 2: Revenue Estimates and Market Potential - Bank of America has cut its revenue estimates for 2026–2030 by 20% to 50% to reflect a more gradual adoption curve for Empaveli, while estimates for another drug, Syfovre, remain largely unchanged [3]. - The initial 5% penetration of the 5,000-patient US market for Empaveli has led analysts to forecast continued financial upside as the drug expands into new indications [1]. Group 3: Company Overview - Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic compounds to address diseases with high unmet needs [4].

As filed with the Securities and Exchange Commission on January 29, 2026. Registration No. 333-292059 ________________________________________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________________________________ STARTON HOLDINGS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) DELAWARE (Jurisdiction of incorporation or organization) _____________________ ...